Urovant Sciences (NASDAQ:UROV) issued its quarterly earnings results on Tuesday. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02), Morningstar.com reports.
NASDAQ UROV opened at $7.54 on Wednesday. Urovant Sciences has a 1-year low of $4.05 and a 1-year high of $14.49. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.34 and a current ratio of 8.34. The firm has a 50-day moving average of $8.24. The company has a market cap of $227.55 million and a price-to-earnings ratio of -1.70.
Several brokerages have issued reports on UROV. HC Wainwright set a $28.00 price target on Urovant Sciences and gave the stock a “buy” rating in a research note on Monday, June 24th. ValuEngine raised Urovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Finally, JPMorgan Chase & Co. set a $24.00 target price on Urovant Sciences and gave the company a “buy” rating in a research note on Friday, June 14th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $21.63.
A number of large investors have recently made changes to their positions in UROV. Barclays PLC purchased a new position in Urovant Sciences during the 4th quarter valued at about $37,000. Marshall Wace North America L.P. purchased a new position in Urovant Sciences during the 1st quarter valued at about $49,000. Two Sigma Investments LP purchased a new position in Urovant Sciences during the 4th quarter valued at about $72,000. Northern Trust Corp increased its holdings in Urovant Sciences by 55.8% during the 2nd quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock valued at $136,000 after purchasing an additional 6,144 shares during the period. Finally, Marshall Wace LLP purchased a new position in Urovant Sciences during the 1st quarter valued at about $325,000. Institutional investors own 21.91% of the company’s stock.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.